They reported that blocking IL-4/IL-13 signalling with dupilumab decreased the TEWL in AD lesions, normalized the lipid composition and increase the ceramide chain length in lesional as well as non-lesional SC of AD patients (Berdyshev et al., 2022). Here, IL4 is linked to Alzheimer disease.